Everyone Healthy Library
Condition / disease reference page from the Everyone Healthy database.
Connected health information
Condition overview
No related signs or symptoms are listed yet.
No linked drugs are listed yet.
Grouped by treatment type. These are educational database links, not personal treatment recommendations. Evidence labels are shown only where stored in the EH database.
No linked treatment or supportive options are listed yet.
These are pulled from both EH diagnostic-test link tables, including the older large test-link table.
This visual map uses existing EH database links to show biological agents and lab markers reported as increased, decreased, or associated with this condition. These are educational relationships only; test results must be interpreted by a qualified clinician because ranges vary by lab, method, age, sex and clinical context.
No markers in this group.
Introduction / full article
Hemoglobin C (abbreviated as Hb C or HbC) is an abnormal hemoglobin with substitution of a lysine residue for glutamic acid residue at the 6th position of the β-globin chain.[1] This mutated form reduces the normal plasticity of host erythrocytes causing a hemoglobinopathy. In those who are heterozygous for the mutation, about 28–44% of total hemoglobin (Hb) is HbC, and no anemia develops. In homozygotes, nearly all Hb is in the HbC form, resulting in moderate normocytic hemolytic anemia. Target cells, microspherocytes and HbC crystals are found in a blood smear from a homozygous patient. Individuals heterozygous for both HbC and Hb S (Hb SC disease) or for HbC and thalassemia are known, and have atypical hemolytic anemias; sickling is enhanced in Hb SC disease. Hemoglobin C is found predominantly in West Africa and has been shown to protect against severe malaria.
